Robert E. Fischell

Chairman Of The Board and Chief Technical Officer

Dr. Robert E. Fischell received his BSME degree from Duke University and MS and Sc.D. degrees from the University of Maryland. Dr. Fischell was employed at the Johns Hopkins University where he was the Chief Engineer of the Space Department and worked on more than 50 spacecraft. His interests at Johns Hopkins then turned to the invention of new medical devices such as pacemakers and implantable heart defibrillators. Starting in 1969, Dr. Fischell began the formation of 14 private companies that licensed his patents on medical devices. These companies include Pacesetter Systems, Inc. (now called St. Jude Medical), IsoStent, Inc., NeuroPace, Inc., Neuralieve, Inc., Angel Medical Systems, Inc, and Svelte Medical Systems, Inc. Dr. Fischell is a prolific inventor with over 200 issued U.S. and foreign patents, many of which have been the basis for new medical device companies.

Dr. Fischell's honors include Inventor of the Year for the USA in 1984, election to the National Academy of Engineering in 1989, the Distinguished Physics Alumnus Award of the University of Maryland, and several medals for distinguished accomplishments in science, engineering and innovation. In 2004 Discover magazine gave Dr. Fischell their annual award of Technology for Humanity.

David R. Fischell Ph.D.

CEO, Angel Medical Systems

Dr. David Fischell is a serial entrepreneur who has founded nine biomedical device companies in the last 15 years, including Angel Medical Systems, a company which has developed an implantable heart attack detection and patient alerting system. Other companies he has founded include Neuralieve, Inc (2002), NeuroPace, Inc. (1997), and Svelte Medical Systems, Inc. Dr. Fischell joined Bell Laboratories in 1979 where, for 11 years, he performed and directed a wide range of research and development projects. He currently holds 89 issued U.S. patents with 67 pending, and has published numerous papers in the fields of telecommunications, cardiology, radiobiology, and radiation dosimetry. He is a director of seven biomedical technology companies including five of those he founded. He was also the primary designer of the VelocityTM and CypherTM coronary stents for Cordis, a Johnson & Johnson Company. He is a Trustee of Cornell University, Chairman of the Cornell University Biomedical Engineering Advisory Board, a member of IEEE, the American Epilepsy Society, the Biomedical Engineering Society and a Fellow of the American Institute for Medical and Biological Engineering.

Steve Burpee

President, Burpee Materials Technology, LLC

Steve Burpee is COO and President of Burpee Materials Technology, LLC. Mr. Burpee is a chemical engineer with 25 years of experience in the medical device and aerospace industries in process engineering and materials R & D. His background in surface science and chemical engineering has been the source of most of BMT's proprietary surface finishing technology.

Steve is the team leader of Svelte design, development, and manufacturing work at BMT. He developed most of the BMT processes used to make Svelte stents, but now enjoys a great deal of support improving and assuring those processes. Steve also plays a minor role in Svelte Medical Systems, Inc. design and testing work.

Daniel J. Bowen

CEO, Dempsey Ventures, LLC

Daniel J. Bowen is founder and CEO of Dempsey Ventures, LLC, a holding company that acquires and manages medical device companies. Dempsey Ventures makes full or partial investments in device companies and actively manages and participates in the governance, operations and management of those companies. Founded in 2006, Dempsey Venture’s current portfolio includes Aspen Surgical, Svelte Medical Systems, Ostial Solutions, SunMed and Bay Medical.

Prior to founding Dempsey Ventures, Mr. Bowen served as President and CEO of Aspen Surgical, a medical supply manufacturer. Under Dan’s management, the company grew to over 175 employees with a second manufacturing facility in Redditch, England. He started Aspen in 1999 with an acquisition of products from Imagyn Medical Technologies. Dan began his career in the healthcare industry at Baxter Healthcare (now Cardinal Health) working in several positions and eventually leaving the company after serving as a regional sales manager and corporate account executive.

Dan is active in several community organizations. He currently is a member of the Finance Committee for Spectrum Health Hospitals, a member of the Development Board for the Catholic Secondary Schools and is a member of the board of Immaculate Heart of Mary School.

Robert J. Flanagan

Executive Vice President, Clark Enterprises, Inc.

Robert J. Flanagan is Executive Vice President of Clark Enterprises, Inc. (“Clark”), a Bethesda, Maryland based holding company that is the ownership, investment, and asset management arm of the various Clark entities. Clark is one of the largest privately-held companies in the Washington metropolitan area, with particular interests in construction, real estate and private equities.

With a diverse business background that ranges from professional sports to technology, Mr. Flanagan oversees the acquisition, management and development of new investment opportunities for Clark. In a complimentary role, Mr. Flanagan also serves as Managing Director of CNF Investments LLC, the private equity division of CEI. Since its inception in 1999, Mr. Flanagan has overseen the growth in CNF to its current status as one of the region’s more dynamic investment funds. In this capacity, he is a member of the board of directors of Angel Medical Systems, Clark Construction Group, Eagle Oil & Gas Co, ILD Telecommunications, Inc., Martek Biosciences Corp., MonoSolRX LLC, OfficeArrow, TARP Worldwide and Svelte Medical Systems.

Prior to joining Clark, Mr. Flanagan was the treasurer, secretary and member of the board of directors of Baltimore Orioles, Inc. and began his career in Washington, DC as a member of Arthur Andersen’s audit division.

Mina Sooch

Managing Director, AP John Ventures

Mina Sooch is a Founder and Managing Director of Apjohn Ventures, an early stage life sciences VC fund based in Michigan with nine portfolio companies. Mina has served in board roles for all nine private and public companies and serves as board member and incoming chairman of the Michigan Venture Capital Association.

Prior to VC, Mina served as a Global Account Manager at Monitor Group, a top tier global strategy consulting firm based in Boston, with large pubic healthcare clients and private equity firms. She has worked on over 30 M&A deals including the $7B Pharmacia & Upjohn merger.

Mina began her career in R&D at Ford Motor Company, Dow Chemical Company, and Proctor and Gamble. Mina received a MBA from Harvard Business School in 1993. She was a commencement speaker and graduated summa cum laude with a B.S. in Chemical Engineering from Wayne State University in 1989.